)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
L&C BIO
L&C BIO (290650) investor relations material
L&C BIO Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary13 Nov, 2026
Executive summary
9M 2026 consolidated revenue was ₩107.5bn, operating income ₩24.4bn and net loss ₩20.5bn; revenue and operating profit exceeded the prior-year period, while the net loss narrowed.
Growth remained concentrated in human tissue grafts, with expansion supported by new product launches, a broader medical-device pipeline and planned China production.
Financial highlights
9M revenue reached ₩107.5bn versus ₩60.8bn in 9M 2025; Q3 revenue was ₩38.4bn versus ₩22.6bn.
9M operating income was ₩24.4bn versus ₩2.9bn; consolidated net loss narrowed to ₩20.5bn from ₩66.3bn.
9M operating cash flow was ₩27.7bn versus ₩6.5bn; cash and cash equivalents totaled ₩46.7bn at Sep. 30, 2026.
Standalone 9M revenue was ₩86.7bn; operating income was ₩25.7bn and net loss was ₩18.8bn.
Outlook and guidance
MegaFill Putty was scheduled for production and launch in Q4 2026 after process validation and regulatory reporting; MegaShield production resumption and formal production were also targeted for Q4.
RB.Derm X was targeted for launch in Q1 2027; Re2O, Re2O Fine and Re2O V were listed as launched, while Re2O Plus development was complete with non-clinical testing planned for early 2027.
MegaDerm Plus China local-production approval review was applied for in March 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from L&C BIO
- H1 2026 revenue reached KRW 69.1B, with improved net loss and major global expansion.290650
Q2 2026 - Strong revenue and margin growth offset by large non-cash losses from derivatives and impairment.290650Q4 2025
- H1 2024 saw lower sales and profit, but strategic investments and R&D support future growth.290650Q2 2024
- Q1 2026 revenue and profit surged, supported by core tissue grafts and China expansion.290650Q1 2026
- H1 2025 saw a net loss amid lower sales, but strategic acquisitions and R&D investment continue.290650Q2 2025
- Revenue fell and net loss widened, but global expansion and R&D investment continued.290650Q3 2025
- Net income soared to KRW 141.0 billion on 9.4% revenue growth, driven by a major one-off gain.290650Q4 2024
- Q1 2025 posted a net loss amid robust R&D, global expansion, and new capital initiatives.290650Q1 2025
- Q3 2024 revenue and profit fell sharply year-over-year, but R&D and global expansion continue.290650Q3 2024
Next L&C BIO earnings date
Q4 202617 Feb, 2027
L&C BIO
Next L&C BIO earnings date
Q4 202617 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)